123.5K
Downloads
195
Episodes
Listen in as Katie Lockwood, MD, a primary care pediatrician at Children’s Hospital of Philadelphia, discusses hot topics in primary care with CHOP subject-matter-experts as they weigh in on issues affecting the daily practice of pediatricians. This podcast is for general informational and educational purposes only and is not to be considered as medical advice for any particular patient. Clinicians must rely on their own informed clinical judgment in making recommendations to their patients. ©2017 by Children’s Hospital of Philadelphia, all rights reserved.
Episodes
5 days ago
5 days ago
Tzield or Teplizumab, is a CD3-directed monoclonal antibody to delay the onset of Stage 3 Type 1 Diabetes in adults and pediatric patients aged 8 years and older. This is an important new treatment option because when diabetes is recognized in the early stages (Stage 2), there is an approved treatment that has been shown to delay the need for insulin by about 2-3 years. In this episode, Neha S. Patel, DO, who is an Associate Professor of Pediatrics and an attending physician in the Division of Pediatric Endocrinology and Diabetes at Children's Hospital of Philadelphia, teaches us what we need to know about Tzield and how patients can access it.
No comments yet. Be the first to say something!